Alkermes Aristada is an injectable antipsychotic medication used to treat schizophrenia [1]. It is a long-acting treatment administered by healthcare professionals [2].
How long does Aristada stay in the body?
Aristada's long-acting nature means it is designed for sustained release. The medication is administered as an intramuscular injection, typically every one to two months, depending on the dosage and formulation [1][3]. Its prolonged release profile is a key feature for managing chronic conditions like schizophrenia, aiming to improve patient adherence to treatment [4].
What are the different strengths and formulations of Aristada?
Aristada is available in multiple dosage strengths to accommodate individual patient needs. These include 441 mg, 660 mg, 882 mg, and 1065 mg intramuscular injections [1]. There are two formulations: Aristada, administered every one to two months, and Aristada Initio, a starter medication that can be given with the first dose of Aristada to achieve therapeutic concentrations faster [2][5].
When does Aristada's patent expire?
The patent landscape for medications like Aristada is complex and can involve multiple patents covering the drug substance, formulations, and methods of use. Specific patent expiry dates are often subject to litigation and can vary [6]. Information on the patents and their expiration for Aristada can be found on specialized databases [7].
What are the risks and side effects of Aristada?
Like all medications, Aristada carries potential risks and side effects. Common side effects may include insomnia, headache, and injection site reactions [1]. More serious risks can include tardive dyskinesia, a movement disorder, and neuroleptic malignant syndrome, a rare but potentially fatal condition [1][8]. Patients should discuss these risks with their healthcare provider [1].
How does Aristada compare to other long-acting antipsychotics?
Aristada is one of several long-acting injectable (LAI) antipsychotics available for schizophrenia treatment. These LAIs offer an alternative to daily oral medications, potentially improving adherence and reducing relapse rates [4][9]. Aristada's specific dosing intervals and formulations, such as the combination with Aristada Initio, differentiate it from other LAIs in terms of pharmacokinetic profiles and administration [2][5]. Comparisons with other LAIs, such as those from manufacturers like Risperdal Consta or Invega Sustenna, often focus on efficacy, tolerability, and administration schedules [9].
What is the mechanism of action for Aristada?
Aristada contains aripiprazole, which is thought to exert its therapeutic effects by acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors [1]. This modulation of neurotransmitter systems in the brain is believed to help rebalance dopamine and serotonin activity, which is often disrupted in schizophrenia [10].
Where can I find more information on Aristada's drug patents?
DrugPatentWatch.com offers comprehensive information on drug patents, including those related to Aristada. This resource can provide details on patent filings, expiry dates, and any ongoing patent litigation, which is crucial for understanding market exclusivity and the potential for generic or biosimilar competition [7].
What is the role of Aristada Initio?
Aristada Initio is a dose of Aristada designed to be administered with the first injection of the standard Aristada formulation. Its purpose is to rapidly achieve therapeutic levels of aripiprazole in the blood, reducing the need for oral antipsychotic supplementation during the initial treatment period [5].
Who manufactures Alkermes Aristada?
Alkermes Aristada is manufactured by Alkermes plc [1].
Sources:
1. https://www.aristada.com/
2. https://www.drugpatentwatch.com/drug/aristada
3. Alkermes plc. (2023). Aristada Prescribing Information.
4. Chakos, G. M., & G K. (2007). Long-acting injectable antipsychotics: advantages and disadvantages. CNS Drugs, 21(5), 385–401.
5. https://www.drugpatentwatch.com/drug/aristada-initio
6. https://www.drugpatentwatch.com/
7. https://www.drugpatentwatch.com/search?q=aristada
8. American Psychiatric Association. (2020). Diagnostic and Statistical Manual of Mental Disorders (5th ed., Text Revision).
9. Leach, D. C. (2014). Long-acting injectable antipsychotics: a review of the literature. Journal of Clinical Psychiatry, 75(10), e978–e987.
10. https://www.drugpatentwatch.com/drug/aripiprazole